APPROACHES IN DIVERSE ISSUES OF GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS (GLP-1 RAS) IN GLOBAL HEALTH STRATEGY, ECONOMIC BURDEN, GEOPOLITICAL IMPLICATIONS AND GAIN-OF-FUNCTION RESEARCH

*Dr. Chrysanthus Chukwuma Sr.

ABSTRACT

ABSTRACTGLP-1 receptor agonists are a category of medications which imitate the natural hormone glucagon-like peptide-1 as a therapeutic regimen for type 2 diabetes and obesity. This study endeavours to explore the comprehensive implications of GLP-1 receptor agonists, encapsulating themes of global health strategy, economic burden, geopolitical factors, and gain-of-function (GoF) research. It seeks to supplement to the discourse on the management of type 2 diabetes, obesity and certain chronic diseases while placing GLP-1 therapies as pivotal to multifarious global health paradigms. The author attempts to cover a wide range of primordial issues, challenges and opportunities from scientific and medical spheres to broader socio-economic and political arenas, framing the work at an intersection of diverse interdisciplinary precincts.  Thus, the article illustrates the multidimensional functionalities of GLP-1 receptor agonists (GLP-1 RAs) in treating type 2 diabetes and diverse other dysfunctionalities, for instance, obesity, cardiovascular, hepatic, renal, and neurodegenerative diseases. It also addresses the economic burden, ethical concerns, geopolitical dimensions, critical issues and controversies intertwined with geopolitics and gain-of-function research. The work embraces and tends to link clinical insights with socio-political concerns, highlighting the pertinence for equitable access and sustainable global health strategies. Invariance in the work is that the global society is fit to undertake integrated public health measures in consideration of inter alia both medical innovation and geopolitical equity.

Keywords:

chronic diseases, type 2 diabetes, obesity, LMICs, metformin, medical innovation, geopolitical equity.

Full Text Article